TSX-V:ARCH - TSX Venture Exchange - CA03938C1041 - Common Stock - Currency: CAD
TSX-V:ARCH (3/7/2025, 7:00:00 PM)
1.78
-0.06 (-3.26%)
The current stock price of ARCH.CA is 1.78 CAD. In the past month the price decreased by -5.82%. In the past year, price increased by 1.71%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
IOT.CA | INNOVOTECH INC | N/A | 7.46M |
Arch Biopartners, Inc. is a portfolio-based biotechnology company, which engages in the development of technologies that have the potential to make a significant medical or commercial impact. The company is headquartered in Toronto, Ontario. The firm is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The firm is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The firm has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.
ARCH BIOPARTNERS INC
545 King St W.
TORONTO ONTARIO M5V 1M1 CA
CEO: Richard Muruve
Employees: 0
Company Website: https://archbiopartners.com/
Investor Relations: http://www.archbiopartners.com/investor-hub/
Phone: 16474287031
The current stock price of ARCH.CA is 1.78 CAD. The price decreased by -3.26% in the last trading session.
The exchange symbol of ARCH BIOPARTNERS INC is ARCH and it is listed on the TSX Venture Exchange exchange.
ARCH.CA stock is listed on the TSX Venture Exchange exchange.
7 analysts have analysed ARCH.CA and the average price target is 3.57 CAD. This implies a price increase of 100.56% is expected in the next year compared to the current price of 1.78. Check the ARCH BIOPARTNERS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ARCH BIOPARTNERS INC (ARCH.CA) has a market capitalization of 116.75M CAD. This makes ARCH.CA a Micro Cap stock.
ARCH BIOPARTNERS INC (ARCH.CA) currently has 0 employees.
ARCH BIOPARTNERS INC (ARCH.CA) has a support level at 1.77 and a resistance level at 1.85. Check the full technical report for a detailed analysis of ARCH.CA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ARCH.CA does not pay a dividend.
ARCH BIOPARTNERS INC (ARCH.CA) will report earnings on 2025-05-28.
ARCH BIOPARTNERS INC (ARCH.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.05).
ChartMill assigns a technical rating of 1 / 10 to ARCH.CA. When comparing the yearly performance of all stocks, ARCH.CA is a bad performer in the overall market: 69.4% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ARCH.CA. ARCH.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ARCH.CA reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS decreased by -134.8% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -399.14% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 46% to ARCH.CA. The Buy consensus is the average rating of analysts ratings from 7 analysts.